LIFE IN THE BALANCE

摘要

In May 2008, a research report concluded that it would be too expensive to keep some British people with kidney cancer alive. The 290-page review and economic evaluation had been put together to assess the effectiveness of four new treatments - bevaci-zumab, sorafenib, sunitinib and temsirolimus - for renal-cell carcinoma. The research team concluded that there was some evidence that patients could benefit from these treatments, in some cases even doubling the time that they lived without their disease worsening from five to ten months.